AZN earnings call for the period ending September 30, 2024.…
…
…
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business slows amid a probe…
British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it…
The latest investor updates on stocks that are trending on Tuesday.…
CAMBRIDGE (dpa-AFX) - Eine hohe Nachfrage vor allem nach seinen Medikamenten gegen Krebs und seltene Krankheiten sorgt beim Pharmakonzern Astrazeneca…
AstraZeneca raises 2024 outlook on strong Q3…
The UK’s second-largest listed company by market cap (at the time of writing) presents an opportunity for investors after releasing…
CAMBRIDGE (dpa-AFX) - Nur wenige Tage nach den richtungsweisenden US-Präsidentschaftswahlen hat der britisch-schwedische Pharmakonzern Astrazeneca dort milliardenschwere Investitionen angekündigt.…
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat…
12 November 2024
AstraZeneca invests $3.5 billion
in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment…
12 November 2024
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small…
AstraZeneca
12 November 2024
9M and Q3 2024 results
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum
Revenue and EPS…
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second…
AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday…
…
Two current and two former senior AstraZeneca Plc executives in the group’s China unit are under investigation in a probe…
Toronto (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von BMO Capital Markets:
1. Überblick über die Situation
AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London…
FRANKFURT (dpa-AFX) - Deutsche Bank Research hat Astrazeneca bei einem unveränderten Kursziel von 10500 Pence von "Sell" auf "Hold"…
Charlotte (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von BofA Securities:
Aktuelle Bewertung
Die Analysten von BofA Securities stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292,…
AstraZenecas key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the…
AstraZeneca shares recorded their worst day since March 2020.…
1. Primark owner ABF hikes dividend, buyback as profit jumps “We delivered a substantial improvement in profitability, excellent cash generation…
AstraZeneca PLC (LSE:AZN) shed £15 billion in value on Tuesday following early data on its weight loss drugs and reports dozens…
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 16046 Pence…
ZÜRICH (dpa-AFX Analyser) - Die schweizerische Großbank UBS hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11.300…
1 November 2024 15:00 GMT
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
AstraZenecas China president is under investigation and is cooperating with Chinese authorities, the company said on Wednesday, sending shares down…
This announcement contains inside information
30 October 2024
AstraZeneca China President currently under investigation
Leon Wang, Executive Vice President International and AstraZeneca China…
The CHMP recommends approval for AZNs Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.…
21 October 2024
Wainzua (eplontersen) recommended for approval in the EU by CHMP for the treatment of adult patients with polyneuropathy associated…
Although CSL Behring’s Hizentra (IgPro20) is touted as a key pipeline agent to watch, rheumatologists currently prefer AstraZeneca’s Saphnelo (anifrolumab),…
AstraZeneca, Accenture, AT&T and National Presto Industries are part of the Zacks top Analyst Blog.…
Todays Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), Accenture plc (ACN) and AT&T…
…
7 October 2024
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
AstraZeneca has entered into an exclusive…
…
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating…
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN),…
The FDA grants priority review to AZNs sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in…
1 October 2024 15:00 BST
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct…
The FDA grants priority review to AZNs sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision…
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over Novo…
Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products are part of the Zacks top Analyst Blog.…
26 September 2024
Tagrisso approved in the US for patients with
unresectable, Stage III EGFR-mutated lung cancer
Based on LAURA Phase III trial results which showed Tagrisso
extended…
AZNs key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with…
Todays Research Daily features new research reports on 16 major stocks, including Toyota Motor Corp. (TM), AstraZeneca PLC (AZN) and…
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.…
The FDA approves AstraZenecas Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.…